Cit­ing patent in­fringe­ment, Lipocine sues Clarus; Sang­amo, DBV un­veil share of­fer­ings

→ Meta­bol­ic and en­docrine dis­or­der-fo­cused Lipocine $LPCN on Wednes­day said it was su­ing Clarus Ther­a­peu­tics for its re­cent­ly ap­proved oral testos­terone re­place­ment ther­a­py, Jaten­zo, al­leg­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER